Guardant Health Inc (GH)


Stock Price Forecast

March 28, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Guardant Health Inc chart...

About the Company

we believe conquering cancer is a big data problem. that’s why we built the world’s leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and new products. we’re working on some exciting ones, including in early detection, where the impact on patients can be profound. we’ve raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank.

Sector

Manufacturing

Industry

Dental Laboratories

Employees

2284

CEO

Helmy Eltoukhy

Exchange

NASDAQ

Website

guardanthealth.com

$563M

Total Revenue

2K

Employees

$2B

Market Capitalization

-4.72

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $GH News

Guardant Health: Shield Launch Could Drive Multiple Expansion

6d ago, source:

GH can prove to the market they have a competitive product in Shield can gain a foothold in the roughly 50m unscreened CRC ...

Blood test shows 83% accuracy for detecting colorectal cancer, study finds

on MSN ago, source:

A new screening method for colorectal cancer may be on the horizon. A clinical study showed 83% accuracy for a blood test ...

Buy Rating Affirmed for Guardant Health Amid Strong Shield Test Prospects and Positive ECLIPSE Study Results

14d ago, source:

Canaccord Genuity analyst Kyle Mikson CFA has reiterated their bullish stance on GH stock, giving a Buy rating today. Kyle Mikson CFA has ...

In large trial, Guardant Health’s blood test detects colon cancer, but less reliably at earliest or precancerous stages

15d ago, source: STAT

If approved, Guardant Health’s liquid biopsy is likely to be a strong new addition to colorectal cancer screening tools, particularly for patients who currently choose not to get screened.

Guardant Health Inc (NASDAQ: GH) Is Down -31.09% So Far This Year: What Will Happen Next?

16d ago, source:

The trading price of Guardant Health Inc (NASDAQ:GH) closed lower on Tuesday,March 12, closing at $18.64, -1.84% lower than its previous close. In examining the 52-week price action we see that the ...

Promising new blood test could catch colon cancer early, expand screening options

14d ago, source: KELO Sioux Falls on MSN

A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading ...

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

22d ago, source: TMCnet

The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Guardant, or following a bona fide period of non-employment, as an inducement ...

GH Jul 2024 10.000 put

13d ago, source: Yahoo Finance

The maker of the test, Guardant Health, anticipates an FDA decision this year. PALO ALTO, Calif., March 13, 2024--ECLIPSE study to be published in NEJM shows Shield blood-based screening test detects ...

REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday

13h ago, source:

U.S. stocks were slightly higher, with the S&P 500 gaining around 0.1% on Thursday. Shares of REX American Resources ...

Insiders Buying Advance Auto Parts And 2 Other Stocks

8d ago, source: Hosted on MSN

Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades. When insiders purchase shares, it ...

Blood test shows 83% accuracy for detecting colorectal cancer in trial

on MSN ago, source:

A blood test to screen for colorectal cancer in average-risk individuals without symptoms accurately detected the malignancy ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...